Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMBRIEL: Tozorakimab in adults with uncontrolled asthma on medium- to high-dose ICS
CTR20253511Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tozorakimab in asthma, sponsored by AstraZeneca. Started Jan 2026; status: active.
02
Drugs
tozorakimab
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20253511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253511.